Terevalefim

Research use only, not for human use.

Terevalefim (ANG-3777), an hepatocyte growth factor (HGF) mimetic, selectively activates the c-Met receptor.

Terevalefim (ANG-3777), an hepatocyte growth factor (HGF) mimetic, selectively activates the c-Met receptor.(In Vitro):Terevalefim (ANG-3777) (0-10 μM) significantly inhibited cancer cells proliferation in HUVECs.(In Vivo):Terevalefim (ANG-3777) decreases apoptosis, increases proliferation, and promotes organ repair and function in animal models.Terevalefim (ANG-3777, 40 mg/kg, IP) phosphorylates the c-Met receptor in rats.

Cell Viability Assay Cell Line:Human Umbilical Vein Epithelial Cells (HUVECs).Concentration:0.44, 1.78, and 7.1 μM.Incubation Time:24 to 48 hours.Result:Dose-dependently inhibited cell proliferation.

Animal Model:SD rats.Dosage:40 mg/kg.Administration:IP injection, once.Result:Selectively phosphorylated the c-Met receptor and not other growth factor receptors.

ANG-3777

Angiogenesis

c-Met/HGFR

HMG-CoA Reductase (HMGCR)|Antifungal|sEH|Antioxidant

——

——

1070881-42-3

176.24

C9H8N2S

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (567.41 mM)

N/A

——

(-20℃)

With Ice Pack

≥ 2 years